CN107041880A - 磷酸二酯酶4抑制剂ZL-n-91在制备抗肺癌增殖与转移药物中的应用 - Google Patents
磷酸二酯酶4抑制剂ZL-n-91在制备抗肺癌增殖与转移药物中的应用 Download PDFInfo
- Publication number
- CN107041880A CN107041880A CN201610081083.0A CN201610081083A CN107041880A CN 107041880 A CN107041880 A CN 107041880A CN 201610081083 A CN201610081083 A CN 201610081083A CN 107041880 A CN107041880 A CN 107041880A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- cell
- phosphodiesterase
- inhibitors
- propagation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610081083.0A CN107041880B (zh) | 2016-02-05 | 2016-02-05 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗肺癌增殖与转移药物中的应用 |
PCT/CN2017/078690 WO2017133713A1 (zh) | 2016-02-05 | 2017-03-30 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗肺癌增殖与转移药物中的应用 |
EP17747033.3A EP3412287A4 (en) | 2016-02-05 | 2017-03-30 | APPLICATION OF PHOSPHODIESTERASE 4 INHIBITOR ZL-N-91 IN THE PREPARATION OF DRUGS FOR LUNG CANCER CELL PROLIFERATION AND METASTASES |
AU2017214157A AU2017214157A1 (en) | 2016-02-05 | 2017-03-30 | Application of phosphodiesterase 4 inhibitor ZL-n-91 in preparation of medications for lung cancer proliferation and metastasis |
US16/075,145 US10959977B2 (en) | 2016-02-05 | 2017-03-30 | Application of phosphodiesterase 4 inhibitor ZL-n-91 in preparation of medications for lung cancer proliferation and metastasis |
JP2018560710A JP2019504894A (ja) | 2016-02-05 | 2017-03-30 | 肺がんの増殖および転移に対する薬物の調製におけるPDE4阻害剤ZL−n−91の使用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610081083.0A CN107041880B (zh) | 2016-02-05 | 2016-02-05 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗肺癌增殖与转移药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107041880A true CN107041880A (zh) | 2017-08-15 |
CN107041880B CN107041880B (zh) | 2019-10-01 |
Family
ID=59499420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610081083.0A Active CN107041880B (zh) | 2016-02-05 | 2016-02-05 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗肺癌增殖与转移药物中的应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10959977B2 (zh) |
EP (1) | EP3412287A4 (zh) |
JP (1) | JP2019504894A (zh) |
CN (1) | CN107041880B (zh) |
AU (1) | AU2017214157A1 (zh) |
WO (1) | WO2017133713A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021208295A1 (zh) * | 2020-04-16 | 2021-10-21 | 广州华真医药科技有限公司 | Pde4抑制剂在制备治疗白血病的药物中的应用 |
WO2021208294A1 (zh) * | 2020-04-16 | 2021-10-21 | 广州华真医药科技有限公司 | Pde4抑制剂在制备抑制胶质瘤增殖的药物中的应用 |
CN113876761A (zh) * | 2020-07-01 | 2022-01-04 | 广州华真医药科技有限公司 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用 |
CN114917217A (zh) * | 2022-05-20 | 2022-08-19 | 广东工业大学 | 磷酸二酯酶4抑制剂ZL-n-91在制备治疗三阴性乳腺癌的药物中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
-
2016
- 2016-02-05 CN CN201610081083.0A patent/CN107041880B/zh active Active
-
2017
- 2017-03-30 EP EP17747033.3A patent/EP3412287A4/en not_active Withdrawn
- 2017-03-30 AU AU2017214157A patent/AU2017214157A1/en not_active Abandoned
- 2017-03-30 JP JP2018560710A patent/JP2019504894A/ja not_active Ceased
- 2017-03-30 US US16/075,145 patent/US10959977B2/en active Active
- 2017-03-30 WO PCT/CN2017/078690 patent/WO2017133713A1/zh active Application Filing
Non-Patent Citations (2)
Title |
---|
TANG HF等: "Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
沈健等: "磷酸二酯酶4与肿瘤", 《生命的化学》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021208295A1 (zh) * | 2020-04-16 | 2021-10-21 | 广州华真医药科技有限公司 | Pde4抑制剂在制备治疗白血病的药物中的应用 |
WO2021208294A1 (zh) * | 2020-04-16 | 2021-10-21 | 广州华真医药科技有限公司 | Pde4抑制剂在制备抑制胶质瘤增殖的药物中的应用 |
CN113521053A (zh) * | 2020-04-16 | 2021-10-22 | 广州华真医药科技有限公司 | Pde4抑制剂在制备治疗白血病的药物中的应用 |
CN113521053B (zh) * | 2020-04-16 | 2023-01-10 | 广州华真医药科技有限公司 | Pde4抑制剂在制备治疗白血病的药物中的应用 |
CN113876761A (zh) * | 2020-07-01 | 2022-01-04 | 广州华真医药科技有限公司 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用 |
WO2022000708A1 (zh) * | 2020-07-01 | 2022-01-06 | 广州华真医药科技有限公司 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用 |
CN113876761B (zh) * | 2020-07-01 | 2022-12-20 | 广州华真医药科技有限公司 | 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用 |
CN114917217A (zh) * | 2022-05-20 | 2022-08-19 | 广东工业大学 | 磷酸二酯酶4抑制剂ZL-n-91在制备治疗三阴性乳腺癌的药物中的应用 |
CN114917217B (zh) * | 2022-05-20 | 2023-09-12 | 广东工业大学 | 磷酸二酯酶4抑制剂ZL-n-91在制备治疗三阴性乳腺癌的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2017214157A1 (en) | 2018-09-13 |
CN107041880B (zh) | 2019-10-01 |
US20180369188A1 (en) | 2018-12-27 |
EP3412287A1 (en) | 2018-12-12 |
JP2019504894A (ja) | 2019-02-21 |
EP3412287A4 (en) | 2019-12-25 |
US10959977B2 (en) | 2021-03-30 |
WO2017133713A1 (zh) | 2017-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis | |
CN107041880A (zh) | 磷酸二酯酶4抑制剂ZL-n-91在制备抗肺癌增殖与转移药物中的应用 | |
CN107714686A (zh) | 磷酸二酯酶4抑制剂ZL‑n‑91在制备治疗前列腺癌增生和转移药物中的应用 | |
CN101687792B (zh) | 具有快速皮肤和生物膜穿透速度的非甾体抗炎药的前药及其医药用途 | |
Lyu et al. | Scoparone alleviates Ang II‐induced pathological myocardial hypertrophy in mice by inhibiting oxidative stress | |
Dong et al. | Low concentration of caffeine inhibits the progression of the hepatocellular carcinoma via Akt signaling pathway | |
Zhang et al. | Hordenine protects against lipopolysaccharide-induced acute lung injury by inhibiting inflammation | |
Wang et al. | Granulocyte colony-stimulating factor attenuates myocardial remodeling and ventricular arrhythmia susceptibility via the JAK2-STAT3 pathway in a rabbit model of coronary microembolization | |
Heng et al. | Camptothecin Inhibits Neddylation to Activate the Protective Autophagy Through NF-κ B/AMPK/mTOR/ULK1 Axis in Human Esophageal Cancer Cells | |
CN109568299A (zh) | 氨溴索在制备肿瘤化疗药物增效制剂中用途 | |
CN106377496A (zh) | 一种抗癌症的经皮吸收制剂 | |
Osterloh | The discovery and development of Viagra®(sildenafil citrate) | |
CN107569485A (zh) | 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂 | |
CN108703974A (zh) | 肝纤维化小鼠肝癌原位移植瘤模型的构建方法 | |
Kwon et al. | Antiangiogenic effect of ethanol extract of Vigna angularis via inhibition of phosphorylation of VEGFR2, Erk, and Akt | |
CN105063196B (zh) | 蛋白酶体抑制剂与细胞自噬激活剂联合在胆管癌治疗中的应用 | |
Kim et al. | Inhibition of 5-lipoxygenase suppresses vascular endothelial growth factor-induced angiogenesis in endothelial cells | |
CN102836151B (zh) | Brevilin A在制备JAK-STATs信号靶向抑制剂中的应用 | |
Deng et al. | Activation of vagovagal reflex prevents hepatic ischaemia–reperfusion‐induced lung injury via anti‐inflammatory and antioxidant effects | |
CN104997781A (zh) | 水飞蓟宾或其盐在制备增强alk-tki疗效、延缓其耐药的药物中的应用 | |
Zhang et al. | Cell-to-cell crosstalk: a new insight into pulmonary hypertension | |
CN106727603A (zh) | 去甲泽拉木醛在制备治疗胰腺癌的药物中的应用 | |
CN109908129A (zh) | 千层纸素在制备抑制肺癌侵袭转移药物中的应用 | |
CN105030777A (zh) | 增强alk-tki疗效、延缓其耐药的复合物及其制剂 | |
CN112957357B (zh) | 一种靶向klf4泛素化的小分子抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Zijian Inventor after: Li Fanghong Inventor after: Gong Sijia Inventor after: Lin Yan Inventor after: Li Xiaoxi Inventor before: Zhao Zijian Inventor before: Gong Sijia Inventor before: Lin Yan Inventor before: Li Fanghong Inventor before: Li Xiaoxi |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180402 Address after: 510660 Science City Scientific City, Guangzhou high tech Industrial Development Zone, Guangdong Province, No. 3 Applicant after: GUANGZHOU HUAZHEN PHARMACEUTICAL Co.,Ltd. Address before: 211100, No. 118 East Tianyuan Road, Jiangning District, Jiangsu, Nanjing Applicant before: Zhao Zijian |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230926 Address after: 518118 Room 201, building 2, Huahan science and Technology Industrial Park, No. 19, Qiyun West Road, Heping community, Pingshan street, Pingshan District, Shenzhen, Guangdong Patentee after: Shenzhen Hanhui Pharmaceutical Technology Co.,Ltd. Address before: No. 3 Science Research Road, Science City, High tech Industrial Development Zone, Guangzhou City, Guangdong Province, 510660 Patentee before: GUANGZHOU HUAZHEN PHARMACEUTICAL Co.,Ltd. |